Evidence map›Paper›PMID 41054181›Full record

ArticleIranian biomedical journal2024

Immunogenic Potential of a Multi-Peptide Vaccine Construct Against Uropathogenic Escherichia coli-Associated Urinary Tract Infection.

Saeide Mirsharifi, Mehri Habibi, Touraj Rahimi, Fatemeh Foroohi, Mohammad Reza Asadi Karam

Abstract read
In one paragraph

Article in Iranian biomedical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. UropathogenicAntibiotics (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saeide MirsharifiDepartment of Microbiology, ShQ.C., Islamic Azad University, Shahr-e Qods, Iran.
Mehri HabibiBiotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Pasteur Ave., Tehran 1316943551, Iran.
Touraj RahimiDepartment of Plant Production and Genetics, ShQ.C., Islamic Azad University, Shahr-e Qods, Iran.
Fatemeh ForoohiDepartment of Microbiology, ShQ.C., Islamic Azad University, Shahr-e Qods, Iran.
Mohammad Reza Asadi KaramDepartment of Molecular Biology, Pasteur Institute of Iran, Pasteur Ave., Tehran 1316943551, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Urinary tract infection caused by uropathogenic E. coli (UPEC) is a common infectious disease. The growing frequency of antibiotic resistance highlights the need for alternative strategies, such as vaccines, to combat UTIs. This study aimed to evaluate the immunogenicity of a novel vaccine candidate targeting UPEC. Methods: Different bioinformatics servers were used to design a vaccine candidate composed of PapG II and FimH antigens from UPEC, along with the N- (1-173) and C-terminal (401-495) domains of FliC from Salmonella typhimurium. The final construct was cloned into the pET28a vector, expressed, purified, and confirmed using SDS-PAGE and Western blotting. Mice were immunized with the recombinant protein, both with and without alum adjuvant, and antibody responses were measured using ELISA. Results: The final vaccine construct included one domain of PapG II (81 aa) and FimH (83 aa). The conserved domains of FliC were incorporated into the construct. SDS-PAGE and Western blot confirmed the purification of the protein, with a size of 53 kDa. Immunization of mice with PapG.FimH.FliC protein induced significantly higher levels of serum IgG, IgG isotypes, IgA, as well as mucosal IgA and IgG responses compared to the controls (p < 0.05). The addition of alum to the protein significantly enhanced serum IgG1 and IgA and mucosal IgG, compared to the protein without alum (p < 0.05). Conclusion: The vaccine construct induced significant humoral responses in the mouse model, suggesting its potential as a promising candidate against UPEC. However, additional experimental analyses are required to validate the efficacy of the vaccine construct.

Indexed as

Escherichia coli InfectionsEscherichia coli VaccinesUrinary Tract InfectionsUropathogenic Escherichia coliVaccines, SubunitAdhesins, Escherichia coliAnimalsAntibodies, BacterialFemaleFimbriae ProteinsImmunoglobulin GMiceMice, Inbred BALB CProtein Subunit VaccinesAdhesins, Escherichia coliAntibodies, BacterialEscherichia coli VaccinesFimbriae ProteinsfimH protein, E coliImmunoglobulin GProtein Subunit VaccinesVaccines, SubunitFlagellinUrinary tract infectionsUropathogenic Escherichia coliVaccines

Identifiers

PMID41054181
PMCPMC12585150

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.